{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:21:33Z","timestamp":1789608093266,"version":"build-2803163510"},"reference-count":145,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Snowball 2.0 research project","award":["IDOC24\/03"],"award-info":[{"award-number":["IDOC24\/03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The aim of this narrative review is to critically assess the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing albuminuria among patients with type 2 diabetes mellitus within the framework of personalized medicine. By integrating current evidence from clinical trials and meta-analyses, the review highlights how GLP-1RAs not only enhance glycemic control but also reduce blood pressure, induce weight loss, and mitigate inflammatory responses. While these given factors may vary according to individual patient profiles, they also collectively contribute to slowing the progression of diabetic kidney disease (DKD). Additionally, the discussion emphasizes the dual cardiovascular and renal benefits from these agents, underscoring their role in reducing albuminuria and preserving renal function. The review also identifies gaps in knowledge, suggesting future research directions for optimizing patient selection and treatment regimens to maximize therapeutic benefits.<\/jats:p>","DOI":"10.3390\/jpm16020097","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:10:38Z","timestamp":1770376238000},"page":"97","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8958-6711","authenticated-orcid":false,"given":"Ana","family":"Checa-Ros","sequence":"first","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Enfermedades Cardiorrenales y Metab\u00f3licas, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"},{"name":"Aston Institute of Health & Neurodevelopment (AIHN), School of Life & Health Sciences, The Aston Triangle, Aston University, Birmingham B4 7ET, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6805-7738","authenticated-orcid":false,"given":"Owahabanun Joshua","family":"Okojie","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Enfermedades Cardiorrenales y Metab\u00f3licas, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"},{"name":"Snowball Project Group, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Gabriel","family":"Wassouf","sequence":"additional","affiliation":[{"name":"Snowball Project Group, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Yedean","sequence":"additional","affiliation":[{"name":"Snowball Project Group, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6932-6527","authenticated-orcid":false,"given":"Wei-Chung","family":"Hsueh","sequence":"additional","affiliation":[{"name":"Snowball Project Group, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"},{"name":"Department of Dentistry, Universidad Cardenal Herrera-CEU University, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4660-3554","authenticated-orcid":false,"given":"Patryk","family":"Hebda","sequence":"additional","affiliation":[{"name":"Snowball Project Group, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0505-6641","authenticated-orcid":false,"given":"Esther Rodriguez","family":"Llobell","sequence":"additional","affiliation":[{"name":"Snowball Project Group, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta Bianca","family":"Muhmenthaler","sequence":"additional","affiliation":[{"name":"Snowball Project Group, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6374-2212","authenticated-orcid":false,"given":"Martin Duc-Duy","family":"Tran","sequence":"additional","affiliation":[{"name":"Snowball Project Group, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-891X","authenticated-orcid":false,"given":"Luis","family":"D\u2019Marco","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Enfermedades Cardiorrenales y Metab\u00f3licas, Departamento de Medicina y Cirug\u00eda, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, 46115 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"i6505","DOI":"10.1136\/bmj.i6505","article-title":"How to prevent the microvascular complications of type 2 diabetes beyond glucose control","volume":"356","author":"Valencia","year":"2017","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"ref_3","unstructured":"(2026, January 07). World Health Organization: Diabetes. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5812\/nephropathol.9093","article-title":"Diabetic nephropathy and antioxidants","volume":"2","author":"Tavafi","year":"2013","journal-title":"J. Nephropathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"146154","DOI":"10.1155\/2012\/146154","article-title":"Inflammation in Diabetic Nephropathy","volume":"2012","author":"Lim","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/db08-0057","article-title":"Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes","volume":"57","author":"Forbes","year":"2008","journal-title":"Diabetes"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1497449","DOI":"10.1155\/2021\/1497449","article-title":"Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment","volume":"2021","author":"Samsu","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Weinberg Sibony, R., Segev, O., Dor, S., and Raz, I. (2023). Drug Therapies for Diabetes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417147"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"sfaf172","DOI":"10.1093\/ckj\/sfaf172","article-title":"Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD. kidney and cardiovascular outcomes in a real-world setting","volume":"18","author":"Hsiao","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.eprac.2025.04.017","article-title":"Glucagon-like Peptide-1 Receptor Agonists Are Associated with Improved Survival and Reduced Liver-Related Events in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease: A Large Real-World Retrospective Study","volume":"31","author":"Liu","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"ii19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2530952","DOI":"10.1001\/jamanetworkopen.2025.30952","article-title":"GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Klen, J., and Dol\u017ean, V. (2022). Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073451"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1111\/dom.70144","article-title":"Genetic evidence for repurposing GLP-1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti-inflammatory pathways beyond glycaemic control","volume":"27","author":"Yang","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/ndt\/gfaf069","article-title":"How to individualize renoprotective therapy in obese patients with chronic kidney disease: A commentary by the Diabesity Working Group of the ERA","volume":"40","author":"Morales","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurjpc\/zwaf426","article-title":"Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: Challenges and opportunities","volume":"33","author":"Halimi","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shi, S., Ni, L., Gao, L., and Wu, X. (2022). Comparison of Nonalbuminuric and Albuminuric Diabetic Kidney Disease Among Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.871272"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2337\/dc18-1320","article-title":"Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score\u2013Matched Analysis of a Nationwide, Biopsy-Based Cohort Study","volume":"42","author":"Yamanouchi","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diab.32.2.S64","article-title":"The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy","volume":"32","author":"Mogensen","year":"1983","journal-title":"Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Winchester, J.F., Charen, E., Ornillo, C., Sheth, N., and Harbord, N.B. (2015). Diabetic Nephropathy. Principles of Diabetes Mellitus, Springer International Publishing.","DOI":"10.1007\/978-3-319-20797-1_22-1"},{"key":"ref_23","unstructured":"Shukla, U.V., and Tripathy, K. (2023). Diabetic Retinopathy, StatPearls Publishing."},{"key":"ref_24","first-page":"327","article-title":"Resistant hypertension in type 2 diabetes: Prevalence and patients characteristics","volume":"88","author":"Ciobanu","year":"2015","journal-title":"Clujul Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.diabres.2017.02.025","article-title":"Control of lower extremity edema in patients with diabetes: Double blind randomized controlled trial assessing the efficacy of mild compression diabetic socks","volume":"127","author":"Wu","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7839101","DOI":"10.1155\/2017\/7839101","article-title":"Macrovascular Complications in Patients with Diabetes and Prediabetes","volume":"2017","author":"Huang","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tseng, P.-L., Chung, T.-L., and Lee, C.-H. (2023). Association of Metabolic Syndrome and Other Factors with the Presence of Diabetic Nephropathy in Type 2 Diabetic Patients. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20032453"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1038\/s41598-024-54137-2","article-title":"Age at onset of type 1 diabetes between puberty and 30 years old is associated with increased diabetic nephropathy risk","volume":"14","author":"Lin","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.2215\/CJN.02560607","article-title":"Genetic Factors in Diabetic Nephropathy","volume":"2","author":"Freedman","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12933-024-02544-0","article-title":"Genetic predisposition to nephropathy and associated cardiovascular disease in people with type 1 diabetes: Role of the angiotensinI-converting enzyme (ACE), and beyond; a narrative review","volume":"23","author":"Mohammedi","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gde.2018.01.002","article-title":"Genetic basis of diabetic kidney disease and other diabetic complications","volume":"50","author":"Sandholm","year":"2018","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MNH.0b013e328350313e","article-title":"Towards understanding the inherited susceptibility for nephropathy in diabetes","volume":"21","author":"Thomas","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ndt\/gfab045","article-title":"Precision medicine approaches for diabetic kidney disease: Opportunities and challenges","volume":"36","author":"Tye","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Provenzano, M., Maritati, F., Abenavoli, C., Bini, C., Corradetti, V., La Manna, G., and Comai, G. (2022). Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105719"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1681\/ASN.2005101109","article-title":"Diabetic Nephropathy","volume":"17","author":"Susztak","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mota-Zamorano, S., Gonz\u00e1lez, L.M., Robles, N.R., Valdivielso, J.M., Cancho, B., L\u00f3pez-G\u00f3mez, J., and Gervasini, G. (2021). A Custom Target Next-Generation Sequencing 70-Gene Panel and Replication Study to Identify Genetic Markers of Diabetic Kidney Disease. Genes, 12.","DOI":"10.3390\/genes12121992"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/dom.16359","article-title":"Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease\u2014A practical update for clinicians","volume":"27","author":"Beernink","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e2225821","DOI":"10.1001\/jamanetworkopen.2022.25821","article-title":"Association of Albuminuria and Regression of Chronic Kidney Disease in Adults With Newly Diagnosed Moderate to Severe Chronic Kidney Disease","volume":"5","author":"Pasternak","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jha, R., Lopez-Trevino, S., Kankanamalage, H.R., and Jha, J.C. (2024). Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051098"},{"key":"ref_41","first-page":"e32248","article-title":"The Prevalence of Chronic Kidney Disease and Albuminuria in Patients with Type 1 and Type 2 Diabetes Attending a Single Centre","volume":"14","author":"Majeed","year":"2022","journal-title":"Cureus"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ekir.2019.12.011","article-title":"High Prevalence Low Awareness of Albuminuria in the Community Setting in the KDSAP","volume":"5","author":"Zhuo","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care, 48, S239\u2013S251.","DOI":"10.2337\/dc25-S011"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e151\u2013S199","DOI":"10.2337\/dci23-0048","article-title":"Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Scilletta, S., Di Marco, M., Miano, N., Filippello, A., Di Mauro, S., Scamporrino, A., Musmeci, M., Coppolino, G., Di Giacomo, F., and Bosco, G. (2023). Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk. Biomolecules, 13.","DOI":"10.3390\/biom13050752"},{"key":"ref_47","first-page":"102","article-title":"Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria","volume":"18","author":"Viejo","year":"2022","journal-title":"Eur. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/CS20210625","article-title":"Mechanisms of podocyte injury and implications for diabetic nephropathy","volume":"136","author":"Barutta","year":"2022","journal-title":"Clin. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000506634","article-title":"Diabetic Kidney Disease: Challenges, Advances, and Opportunities","volume":"6","author":"Chen","year":"2020","journal-title":"Kidney Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: A clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/gfaa380","article-title":"Precision medicine in diabetic nephropathy and chronic kidney disease","volume":"36","author":"Fliser","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"112292","DOI":"10.1016\/j.diabres.2025.112292","article-title":"Biomarkers in diabetic nephropathy: A comprehensive review of their role in early detection and disease progression monitoring","volume":"226","author":"Wani","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E791","DOI":"10.1152\/ajpendo.00026.2024","article-title":"Advancements in diabetic kidney disease management: Integrating innovative therapies and targeted drug development","volume":"326","author":"Ghose","year":"2024","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Doumani, G., Theofilis, P., Vordoni, A., Thymis, V., Liapis, G., Smirloglou, D., and Kalaitzidis, R.G. (2025). Diabetic Kidney Disease: From Pathophysiology to Regression of Albuminuria and Kidney Damage: Is It Possible?. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178224"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11880","DOI":"10.1016\/S0021-9258(18)67324-7","article-title":"Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing","volume":"261","author":"Mojsov","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1900\/RDS.2011.8.418","article-title":"GLP-1, the Gut-Brain, and Brain-Periphery Axes","volume":"8","author":"Cabou","year":"2011","journal-title":"Rev. Diabet. Stud."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): Cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.tem.2025.01.002","article-title":"Glucagon-like peptide-1 receptor agonism and end-organ protection","volume":"36","author":"Daniels","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kr\u00f3l, M., Kupnicka, P., \u017bychowska, J., Kapczuk, P., Szu\u0107ko-Kociuba, I., Prajwos, E., and Chlubek, D. (2025). Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146777"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., and LeRoith, D. (2023). Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11883-025-01350-7","article-title":"Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations to Optimal Translation","volume":"27","author":"Becker","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s11033-024-09793-y","article-title":"From diabetes to diverse domains: The multifaceted roles of GLP-1 receptor agonists","volume":"51","author":"Dave","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/0113816128375766250720234005","article-title":"An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs","volume":"31","author":"Zayed","year":"2025","journal-title":"Curr. Pharm. Des."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., and Borghi, C. (2025). Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice. Heart.","DOI":"10.1136\/heartjnl-2024-324847"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"106411","DOI":"10.1016\/j.phrs.2022.106411","article-title":"Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics","volume":"184","author":"Reynolds","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_67","unstructured":"(2026, January 07). New Technological Advancements in the Industry. UVTech, C.C. Available online: https:\/\/www.uvtech-cc.com\/news_details\/36.html."},{"key":"ref_68","unstructured":"Novo Nordisk Inc (2025, November 15). Ozempic\u00ae (Semaglutide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209637s020s021lbl.pdf."},{"key":"ref_69","unstructured":"Novo Nordisk Inc (2025, November 15). Wegovy\u00ae (Semaglutide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf."},{"key":"ref_70","unstructured":"Novo Nordisk Inc (2025, November 15). Rybelsus\u00ae (Semaglutide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213051s018lbl.pdf."},{"key":"ref_71","unstructured":"(2026, January 07). Exenatide. Beyond the Dish. Available online: https:\/\/beyondthedish.wordpress.com\/tag\/exenatide\/."},{"key":"ref_72","unstructured":"Astra-Zeneca (2025, November 15). Byetta\u00ae (Exenatide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021773s9s11s18s22s25lbl.pdf."},{"key":"ref_73","unstructured":"Astra-Zeneca (2025, November 15). Bydureon\u00ae (Exenatide Extended-Release) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022200s026lbl.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/VHRM.S4039","article-title":"Potential of liraglutide in the treatment of patients with type 2 diabetes","volume":"199","author":"Deacon","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_75","unstructured":"Novo Nordisk Inc (2025, November 15). Victoza\u00ae (Liraglutide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022341s039lbl.pdf."},{"key":"ref_76","unstructured":"Novo Nordisk Inc (2025, November 15). Saxenda\u00ae (Liraglutide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/206321s016lbl.pdf."},{"key":"ref_77","unstructured":"(2026, January 07). Dulaglutide: Pharmacodynamics, Mechanism of Action, Toxicity. ChemicalBook. Available online: https:\/\/www.chemicalbook.com\/article\/dulaglutide-pharmacodynamics-mechanism-of-action-toxicity.htm."},{"key":"ref_78","unstructured":"Eli Lilly Company (2025, November 15). Trulicity\u00ae (Dulaglutide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125469s036lbl.pdf."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1517\/14656566.2013.838559","article-title":"Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus","volume":"14","author":"Forst","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_80","unstructured":"Sanofi (2025, November 15). Adlyxin\u00ae (Lixisenatide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208471s007lbl.pdf."},{"key":"ref_81","unstructured":"(2026, January 07). Purification of GLP-1 Agonists. YMCS Group. Available online: https:\/\/ymc.eu\/Purification-of-GLP-1-Agonists.html."},{"key":"ref_82","unstructured":"Eli Lilly Company (2026, January 07). Mounjaro\u00ae (Tirzepatide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf."},{"key":"ref_83","unstructured":"Eli Lilly Company (2025, November 15). Zepbound\u00ae (Tirzepatide) Injection for Subcutaneous Use, U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217806s031lbl.pdf."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jch.12660","article-title":"Albuminuria in Hypertensive Patients: Where the Choice of Antihypertensive Medications Matters","volume":"18","author":"Mani","year":"2016","journal-title":"J. Clin. Hypertens."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1008835602894","article-title":"Impact of weight loss on Health-Related Quality of Life","volume":"8","author":"Fontaine","year":"1999","journal-title":"Qual. Life Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/dme.12594","article-title":"Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment","volume":"32","author":"Lajer","year":"2015","journal-title":"Diabet. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e009579","DOI":"10.1136\/bmjopen-2015-009579","article-title":"Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: An acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes","volume":"5","author":"Smits","year":"2015","journal-title":"BMJ Open"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease","volume":"15","author":"Mann","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"F1047","DOI":"10.1152\/ajprenal.00164.2014","article-title":"ANP-induced signaling cascade and its implications in renal pathophysiology","volume":"308","author":"Theilig","year":"2015","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/cvr\/cvac112","article-title":"Cardiovascular effects of incretins: Focus on glucagon-like peptide-1 receptor agonists","volume":"119","author":"Madsbad","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/ndt\/gfaf110","article-title":"GLP-1-based therapeutics for cardiorenal protection in metabolic diseases","volume":"41","author":"Apperloo","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cmet.2023.01.004","article-title":"The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes","volume":"35","author":"Thomas","year":"2023","journal-title":"Cell Metab."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12933-023-01793-9","article-title":"The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","volume":"22","author":"Lin","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wronka, M., Krzemi\u0144ska, J., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2023). New Insights into the Use of Liraglutide\u2014Impact on Cardiovascular Risk and Microvascular Outcomes. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041159"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Doumani, G., Theofilis, P., Tsimihodimos, V., and Kalaitzidis, R.G. (2024). GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?. Life, 14.","DOI":"10.3390\/life14111478"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1038\/s41598-024-55724-z","article-title":"The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function","volume":"14","author":"Wajdlich","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Rroji, M., and Spasovski, G. (2024). Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030657"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: A novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: Post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"EVIDoa2500158","DOI":"10.1056\/EVIDoa2500158","article-title":"Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease","volume":"4","author":"Bartholdy","year":"2025","journal-title":"NEJM Evid."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1159\/000510255","article-title":"Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease","volume":"51","author":"Wang","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Natale, P., Green, S.C., Tunnicliffe, D.J., Pellegrino, G., Toyama, T., and Strippoli, G.F. (2025). Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD015849.pub2"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/dom.14067","article-title":"Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials","volume":"22","author":"Guja","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: A meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2021.12.018","article-title":"Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials","volume":"97","author":"Chalmoukou","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2215\/CJN.0000000584","article-title":"The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes","volume":"20","author":"Moura","year":"2025","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/dom.12816","article-title":"Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase and clinical trials","volume":"19","author":"Tuttle","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Li, W., Liang, X., Sun, N., and Zhang, D. (2025). Influence of glucagon-like peptide-1 receptor agonists on renal parameters: A meta-analysis of randomized controlled trials. BMC Endocr. Disord., 25.","DOI":"10.1186\/s12902-025-01948-7"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2025.20834","article-title":"SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria","volume":"335","author":"Neuen","year":"2026","journal-title":"JAMA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/j.ajkd.2025.03.016","article-title":"Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Sodium\/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure Mortality in Patients with Type 2 Diabetes, CKD","volume":"86","author":"Lee","year":"2025","journal-title":"Am. J. Kidney Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1038\/s41598-019-49525-y","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Bae","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_128","first-page":"CD006257","article-title":"Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease","volume":"2024","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: A narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"103086","DOI":"10.1016\/j.dsx.2024.103086","article-title":"Computational approaches for clinical, genomic and proteomic markers of response to glucagon-like peptide-1 therapy in type-2 diabetes mellitus: An exploratory analysis with machine learning algorithms","volume":"18","author":"Villikudathil","year":"2024","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s00125-022-05732-3","article-title":"A roadmap to achieve pharmacological precision medicine in diabetes","volume":"65","author":"Florez","year":"2022","journal-title":"Diabetologia"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2337\/dbi20-0002","article-title":"Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment","volume":"69","author":"Dennis","year":"2020","journal-title":"Diabetes"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"175356","DOI":"10.1016\/j.ejphar.2022.175356","article-title":"Pharmacogenomics of GLP-1 receptor agonists: Focus on pharmacological profile","volume":"936","author":"Jakhar","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2025.03.003","article-title":"Structural pharmacology and mechanisms of GLP-1R signaling","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2174\/1381612826666201203145654","article-title":"Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management","volume":"27","author":"Kyriakidou","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00125-021-05402-w","article-title":"Pharmacogenetics of novel glucose-lowering drugs","volume":"64","author":"Rathmann","year":"2021","journal-title":"Diabetologia"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Shahisavandi, M., Wang, K., Ghanbari, M., and Ahmadizar, F. (2023). Exploring Metabolomic Patterns in Type 2 Diabetes Mellitus and Response to Glucose-Lowering Medications\u2014Review. Genes, 14.","DOI":"10.3390\/genes14071464"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s00125-024-06099-3","article-title":"Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"67","author":"Cardoso","year":"2024","journal-title":"Diabetologia"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s44446-025-00038-y","article-title":"GLP-1 receptor agonism: A transformative approach for managing type-2 diabetes and obesity","volume":"33","author":"Alharbi","year":"2025","journal-title":"Saudi Pharm. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S2213-8587(23)00232-2","article-title":"Precision medicine of obesity as an integral part of type 2 diabetes management\u2014Past, present, and future","volume":"11","author":"Szczerbinski","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"Khunti","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e70066","DOI":"10.1002\/dmrr.70066","article-title":"Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data","volume":"41","author":"Fishkin","year":"2025","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-023-01829-0","article-title":"Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: Real-world evidence","volume":"22","author":"Schechter","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.kint.2021.10.033","article-title":"GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes","volume":"101","author":"Xu","year":"2022","journal-title":"Kidney Int."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.ajkd.2024.08.003","article-title":"KDOQIUS Commentary on the KDIGO2024 Clinical Practice Guideline for the Evaluation Management of CKD","volume":"85","author":"Navaneethan","year":"2025","journal-title":"Am. J. Kidney Dis."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/97\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:32:59Z","timestamp":1770377579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":145,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jpm16020097"],"URL":"https:\/\/doi.org\/10.3390\/jpm16020097","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}